[{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"T19","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Not Applicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Matrix Partners China","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"T19","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Delayed-release Tablet","sponsorNew":"Triastek \/ Matrix Partners China","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Matrix Partners China"},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"T21","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Not Applicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"T21","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Not Applicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Not Applicable","leadProduct":"T22","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Triastek

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : T22 is a world's first 3D printed gastric retention product. It is being evaluated in preclinical studies for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

                          Brand Name : T22

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          January 31, 2024

                          Lead Product(s) : T22

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : T21 is Triastek’s third 3D printed oral colon-targeted delivery drug product, and is an oral, colon-targeted delivery drug for moderate to severe ulcerative colitis (UC).

                          Brand Name : T21

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          July 20, 2023

                          Lead Product(s) : T21

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : T21 is a novel potential treatment capable of colon-targeted drug delivery. With a unique 3D dosage form design, T21 can reach the targeted colon segment of the GI tract.

                          Brand Name : T21

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          November 21, 2022

                          Lead Product(s) : T21

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The novel design made possible by 3D printing allows T19 to function as a chronotherapeutic drug delivery system, targeting the circadian nature of RA symptoms.

                          Brand Name : T19

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 14, 2021

                          Lead Product(s) : T19

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Matrix Partners China

                          Deal Size : $50.0 million

                          Deal Type : Series B Financing

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : United States Food and Drug Administration (FDA) has approved Triastek's Investigational New Drug (IND) 505(b)(2) application for its first 3D printed drug product – T19, indicated for the treatment of rheumatoid arthritis (RA).

                          Brand Name : T19

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          February 09, 2021

                          Lead Product(s) : T19

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank